**FORM
      10-QSB**




**SECURITIES
      AND EXCHANGE COMMISSION**




**Washington,
      D.C. 20549**




(Mark
        One)
  x
                **REPORT
                    PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF
                    1934**




For
      the
      quarterly period ended March 31, 2007




OR




o
              **REPORT
                  PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF
                  1934**




For
      the
      transition period from  to




Commission
      File No.  **000-29462**





**ADVANCED
      PLANT PHARMACEUTICALS, INC.**


(Exact
      name of registrant as specified in its charter)




Delaware
            
            59-2762023(State
                or other jurisdiction of
              incorporation
                or organization)
            
            (I.R.S.
                Employer
              Identification
                No.)




43
                West 33rdStreet
              New
                York, NY
            
            10001(Address
                of principal executive office)
            
            (Zip
                Code)




Registrant’s
        telephone number, including area code: (212)695-3334







Former
      name, former address and former fiscal year, if changed since last
      report.




Indicate
      by a check mark whether the registrant (1) has filed all reports required
      to be filed by Section 13 or 15 (d) of the Securities Exchange Act of
      1934 during the preceding 12 months (or for such shorter period that the
      registrant was required to file such reports), and (2) has been subject to
      such filing requirements for the past 90 days.




Yes x No o




Indicate
      by a check mark whether the registrant is an accelerated filer (as defined
      in
      Rule 12b-2 of the Exchange Act).




Yes o No x




APPLICABLE
      ONLY TO CORPORATE ISSUERS:




Indicate
      the number of shares outstanding of each of the issuer’s classes of Common Stock
      as of the latest practicable date:




868,382,336
      shares of Common Stock, $.0007 par value as of March
      31,
      2007









**INDEX**




**PART
      I. - FINANCIAL INFORMATION**




Item
                  1. Financial StatementsCondensed
                  Consolidated Balance Sheets at March 31, 2007 (unaudited) and December
                  31,
                  2006
              
              F-1Condensed
                  Consolidated Statements of Operations for the Three Months Ended
                  March 31,
                  2007 and March 31, 2006 (unaudited)
              
              F-2Condensed
                  Consolidated Statements of Cash Flows for the Three Months Ended
                  March 31,
                  2007 and March 31, 2006 (unaudited)
              
              F-3Notes
                  to Interim Financial Statements as of March 31, 2007
                  (unaudited)
              
              F-5Item
                  2Management’s
                  Discussion and Analysis or Plan of Operations
              
              2Item
                  3Controls
                  and Procedures
              
              4**PART
                  II. - OTHER INFORMATION**Item
                  1Legal
                  Proceedings
              
              5Item
                  2Unregistered
                  Sales of Equity Securities and Use of Proceeds
              
              5Item
                  3Defaults
                  upon senior securities
              
              5Item
                  4Submission
                  of matters to a vote of security holders
              
              5Item
                  5Other
                  information
              
              6Item
                  6Exhibits
                  and reports on Form 8-K
              
              6









PART
      I.
      FINANCIAL INFORMATION




**PART
      I. FINANCIAL INFORMATION**




**INDEX
      TO FINANCIAL STATEMENTS**




Balance
                  Sheets
              
              F-1Statements
                  of Operations
              
              F-2Statements
                  of Cash Flows
              
              F-3Notes
                  to Financial Statements
              
              F-5









Item
      1.
      Financial Statements


ADVANCED
        PLANT PHARMACEUTICALS, INC. AND SUBSIDIARIES
  CONSOLIDATED
        BALANCE SHEETS
  March
                    31,
                
                December
                    31,2007
                
                2006UnauditedASSETSCURRENT
                    ASSETSPrepaid
                    consulting expenses
                
                $
                -
                
                $
                7,600Total
                    Current Assets
                
                
                
                
                
                7,600OFFICE
                    EQUIPMENT, net of accumulated depreciation of $4,239and
                    $4,058, respectively
                
                
                114
                
                
                295OTHER
                    ASSETSGoodwill
                
                
                328,648
                
                
                -Due
                    from related companies
                
                
                16,120
                
                
                16,120Other
                    assets
                
                
                5,679
                
                
                5,679350,447
                
                
                21,799Total
                    Assets
                
                $
                350,561
                
                $
                29,694LIABILITIES
                    AND STOCKHOLDERS’ DEFICIENCYCURRENT
                    LIABILITIESBank
                    overdraft
                
                $
                7,248
                
                $
                5,468Accounts
                    payable
                
                
                184,447
                
                
                181,946Accrued
                    expenses
                
                
                433,931
                
                
                425,694Accrued
                    expenses payable in common stock
                
                
                119,096Accrued
                    expenses - stockholders
                
                
                945,861
                
                
                871,549Due
                    to related companies
                
                
                8,484
                
                
                8,484Deposits
                    to acquire stock
                
                
                100,000Acquisition
                    payable in common stock
                
                
                300,000Loan
                    payable
                
                
                5,000Loans
                    payable - stockholders
                
                
                332,470
                
                
                305,993Total
                    Current Liabilities
                
                
                2,436,537
                
                
                1,799,134STOCKHOLDERS’
                    DEFICIENCYPreferred
                    stock, authorized 10,000,000 shares;$0.0007
                    par value; 5,000,000 shares issuedand
                    outstanding at March 31,2007
                    and December 31, 2006
                
                
                3,500
                
                
                3,500Common
                    stock, authorized 880,000,000shares;
                    $0.0007 par value; 880,000,000 and875,157,996
                    shares issued and outstanding atMarch
                    31, 2007 and December 31, 2006
                
                
                616,000
                
                
                612,611Additional
                    paid-in capital
                
                
                22,147,468
                
                
                21,982,453Accumulated
                    deficit
                
                
                (24,852,944
                )
                
                (24,368,004
                )Total
                    Stockholders’ Deficiency
                
                
                (
                    2,085,976
                )
                
                (1,769,440
                )Total
                    Liabilities and Stockholders’ Deficiency
                
                $
                350,561
                
                $
                29,694
 
 See
        accompanying notes to financial statements.
 
 F-1
 
 ADVANCED
        PLANT PHARMACEUTICALS, INC. AND SUBSIDIARIES
  CONSOLIDATED
        STATEMENTS OF OPERATIONS (UNAUDITED)
  For
                    the Three Months Ended March
                    31,2007
                
                
                2006REVENUE
                    - SALES
                
                $
                4,037
                
                $
                1,976COSTS
                    AND EXPENSESCost
                    of goods sold
                
                
                578Salaries
                    and consulting fees - stockholders'
                
                
                79,500
                
                
                79,500Selling,
                    general and administrative expenses
                
                
                408,671
                
                
                24,024Depreciation
                
                
                181
                
                
                279Total
                    Costs and Expenses
                
                
                488,930
                
                
                103,803NET
                    OPERATING LOSS
                
                
                (484,893
                )
                
                (101,827
                )OTHER
                    EXPENSEInterest
                    expense
                
                
                (47
                )
                
                (4,043
                )LOSS
                    BEFORE DISCONTINUED OPERATIONS
                
                
                (484,940
                )
                
                (105,870
                )Loss
                    from discontinued operations
                
                
                
                
                
                (532,904
                )NET
                    LOSS
                
                $
                (484,940
                )
                $
                (638,774
                )NET
                    LOSS PER SHARE OF COMMON STOCKLoss
                    before discontinued operations (basic and fully diluted)
                
                $
                (
                    0.001
                )
                $
                (0.000
                )Net
                    loss (basic and fully diluted)
                
                $
                (
                    0.001
                )
                $
                (0.001
                )WEIGHTED
                    AVERAGE NUMBER OF COMMONSHARES
                    OUTSTANDING (basic and fully diluted)
                
                
                879,801,177
                
                
                798,157,996
  See
        accompanying notes to financial statements.
 
 F-2
 
 ADVANCED
        PLANT PHARMACEUTICALS, INC. AND SUBSIDIARIES
  CONSOLIDATED
        STATEMENTS OF CASH FLOWS (UNAUDITED)
  For
                    the Three Months Ended March
                    31,2007
                
                2006CASH
                    FLOWS FROM OPERATING ACTIVITIESNet
                    loss
                
                $
                (484,940
                )
                $
                (638,774
                )Adjustments
                    to reconcile net loss to cash flowsused
                    in operating activitiesStock
                    issued for services
                
                
                273,500
                
                
                324,000Depreciation
                    expense
                
                
                181
                
                
                279Changes
                    in assets and liabilities:Decrease
                    in accounts receivable
                
                
                
                
                
                1,188Decrease
                    in prepaid expenses - officers
                
                
                
                
                
                6,700Increase
                    in prepaid offering costs
                
                
                
                
                
                (5,000
                )Decrease
                    in prepaid consulting expenses
                
                
                7,600Increase
                    in due from related company
                
                
                
                
                
                (2,250
                )Increase
                    in accounts payable
                
                
                36,501
                
                
                25,930Increase
                    in accrued expenses
                
                
                8,237
                
                
                40,182Increase
                    in accrued expenses - shareholders
                
                
                74,312
                
                
                111,505Net
                    cash used in operating activities
                
                
                (84,609
                )
                
                (136,240
                )CASH
                    FLOWS FROM INVESTING ACTIVITIESNet
                    cash (used in) provided by investing activitiesCASH
                    FLOWS FROM FINANCING ACTIVITIESCash
                    received in acquisition of subsidiary
                
                
                1,417Bank
                    overdraft
                
                
                1,780
                
                
                119Proceeds
                    from loan payable
                
                
                5,000Proceeds
                    from loans payable - stockholders’
                
                
                28,412Payments
                    on loans payable - stockholders’
                
                
                (2,000
                )Proceeds
                    from deposits to acquire stock
                
                
                50,000
                
                
                150,000Net
                    cash provided by financing activities
                
                
                84,609
                
                
                150,119Net
                    increase (decrease) in cash
                
                
                -
                
                
                13,879CASH
                    AT BEGINNING OF PERIOD
                
                
                -
                
                
                11,688CASH
                    AT END OF PERIOD
                
                $
                -
                
                $
                25,567SUPPLEMENTAL
                    DISCLOSURE OF CASH FLOWS INFORMATIONInterest
                    paid
                
                $
                47
                
                $
                4,043
  See
        accompanying notes to financial statements.
  F-3
  ADVANCED
        PLANT PHARMACEUTICALS, INC AND SUBSIDIARIES
  CONSOLIDATED
        STATEMENTS OF CASH FLOWS (UNAUDITED) (CONTINUED)
 For
                    the Three Months Ended March
                    31,2007
                
                2006NON-CASH
                    INVESTING AND FINANCING ACTIVITIESIssuance
                    of common stock as compensation
                
                $
                273,500Issuance
                    of Mazal common stock for services classified asa
                    deferred credit
                
                
                
                
                $
                324,000Issuance
                    of common stock in satisfaction of accounts payable
                
                
                40,200Common
                    stock in excess of authorized number of sharesreclassified
                    to accrued expenses payable in common stock
                
                
                119,096Common
                    stock in excess of authorized number of sharesreclassified
                    to deposits to acquire stock
                
                
                50,000Assets
                    acquired and liabilities assumed in acquisition ofsubsidiary:Cash
                
                
                1,417Due
                    from related company
                
                
                5,618Goodwill
                
                
                328,648Loans
                    payable - stockholder
                
                
                (5,683
                )Acquisition
                    payable in common stock
                
                
                (300,000
                )Issuance
                    of common stock
                
                
                (30,000
                )
  See
          accompanying notes to financial statements.





F-4




ADVANCED
        PLANT PHARMACEUTICALS, INC. AND SUBSIDIARIES
 
 NOTES
        TO
        FINANCIAL STATEMENTS
 March
        31,
        2007
 
 1.
        CONDENSED FINANCIAL STATEMENTS
 
 In
        the
        opinion of the Company, the accompanying unaudited condensed financial
        statements include all adjustments (consisting only of normal recurring
        accruals) which are necessary for a fair presentation of the results for
        the
        periods presented. Certain information and footnote disclosure, normally
        included in the financial statements prepared in accordance with generally
        accepted accounting principles, have been condensed and omitted. The results
        of
        operations for the three months ended March 31, 2007 are not indicative of
        the
        results of operations for the year ended December 31, 2007. The condensed
        financial statements should be read in conjunction with the Company’s financial
        statements included in its annual Form 10 KSB for the year ended December
        31,
        2006.
 
 2.
        PRINCIPLES OF CONSOLIDATION
 
 The
        consolidated financial statements for the three months ended March 31, 2007,
        include the accounts of Advanced Plant Pharmaceuticals, Inc. (“APPI”) and its
        wholly owned subsidiary World Health Energy, Inc. (“WHE”) acquired on February
        8, 2007. The results of operations for WHE are included from January 1, 2007
        through March 31, 2007 as WHE had minimal operating activity. All intercompany
        transactions have been eliminated.
 
 WHE
        has
        the technical knowledge to operate Bio-Diesel fuel plants.
 
 3.
        STOCK
        WARRANTS
 
 At
        March
        31, 2007, the Company had outstanding warrants to purchase 7,000,000 shares
        of
        the Company's common stock at a price of $.03 per share. The warrants are
        exercisable and expire at various dates through 2007.
 
 4.
        COMMITMENTS AND CONTINGENCIES
 
 The
        Company has employment agreements with two employees, and a consulting contract
        with a key consultant, who are also stockholders of the Company. At March
        31,
        2007, the Company has a total liability for accrued salaries and consulting
        expense to stockholders of $805,550. There could be certain payroll tax
        liabilities owed to the IRS on some of the payments for services to certain
        consultants that were paid in prior years, pursuant to these employment
        agreements.
 
 5.
        ACCRUED EXPENSES PAYABLE IN COMMON STOCK
 
 Accrued
        expenses payable in common stock in the amount of $119,096 represents the
        value
        of 32,157,996 shares of common stock approved for issuance by the Company’s
        director. These shares were recorded as issued and outstanding in 2005 and
        2006
        for services rendered pursuant to unanimous consents of the sole director
        of the
        Company, contracts and agreements. The shares were reclassified from common
        stock and additional paid-in capital in January 2007 as the Company issued
        stock
        through its stock transfer agent to others that exceeded the number of shares
        of
        common stock authorized for issuance by the Company pursuant to its Articles
        of
        Incorporation. See Note 7.
 
 6.
        DEPOSITS TO ACQUIRE STOCK
 
 The
        deposits to acquire common stock include $50,000 received as part of a letter
        of
        intent with H & H Equipment Company, Inc. (“H&H”) to provide $1,200,000
        for the construction of two Bio-Diesel plants for the Company in exchange
        for a
        33% interest in the Company in the form of convertible preferred
        stock.
  F-5
  ADVANCED
        PLANT PHARMACEUTICALS, INC. AND SUBSIDIARIES
 
 NOTES
        TO
        FINANCIAL STATEMENTS
 March
        31,
        2007
 
 6.
        DEPOSITS TO ACQUIRE STOCK (CONTINUED)
  Deposits
        to acquire stock, also includes $50,000 received from Ezriel Silberberg pursuant
        to a stock purchase agreement to acquire 25,000,000 shares of the Company’s
        common stock. The proceeds were received in 2006 and the shares were included
        in
        shares issued and outstanding at December 31, 2006. The deposit was reclassified
        from common stock and additional paid-in capital in January 2007 as the Company
        issued stock through its stock transfer agent to others and exceeded the
        number
        of shares of common stock authorized for issuance by the Company pursuant
        to it
        Articles of Incorporation. See Note 7.
  7.
        ISSUANCE OF COMMON STOCK
  The
        Company’s Articles of Incorporation allow for the issuance of no more than
        880,000,000 shares of its common stock. At March 31, 2007, the Company has
        approved through the approval of unanimous consents of the sole director
        of the
        Company, and executed contracts and agreements with numerous third parties,
        the
        issuance of 107,157,996 in excess of the authorized number of shares allowed
        to
        be issued. In addition, common stock issued and outstanding at March 31,
        2007
        includes 11,592,004 approved for issuance by the Company but which have not
        been
        issued by the Company’s stock transfer agent.
  On
        January 4, 2007, the Company issued 4,000,000 shares of its common stock
        to its
        attorneys in consideration of accrued legal services at $0.0072 per share.
        The
        aggregate remuneration of $28,800 has been treated as payment of accrued
        liabilities to the attorneys.
  On
        January 8, 2007, the Company issued 6,000,000 shares of its common stock
        to a
        consultant as a penalty for late payment at $0.0063 per share. The aggregate
        remuneration of $37,800 has been treated as stock based compensation and
        expensed in the current year.
  On
        January 25, 2007, the Company issued 30,000,000 shares of its common stock
        to a
        consultant for services at $0.0053 per share. The aggregate remuneration
        of
        $159,000 has been treated as stock based compensation and expensed in the
        current period.
  On
        February 1, 2007, the Company issued 15,000,000 shares of its common stock
        to a
        consultant for services at $0.0047 per share. The aggregate remuneration
        of
        $70,500 has been treated as stock based compensation and expensed in the
        current
        period.
  On
        February 8, 2007, the Company issued 5,000,000 shares of its common stock
        to
        acquire a 100% interest in World Health Energy Inc. (“WHE”) at $0.006 per share.
        In addition, the Company recorded a liability for the future issuance of
        an
        additional 50,000,000 shares of its common stock at $0.006 per share as part
        of
        the acquisition of WHE. The aggregate value of the acquisition was $330,000,
        of
        which $30,000 represented the value of the common stock issued and $300,000
        represented the liability for future issuance of shares and is classified
        as
        acquisition payable in common stock.
  On
        February 13, 2007, the Company issued 1,000,000 shares of its common stock
        to
        its attorneys for legal services at $0.0062 per share. The aggregate
        remuneration of $6,200 has been treated as legal fees and expensed in the
        current period.
  On
        February 21, 2007, the Company issued 1,000,000 shares of its common stock
        to
        its attorneys in consideration of legal services at $0.0052 per share. The
        aggregate remuneration of $5,200 has been treated as payment of accrued
        liabilities to the attorneys.
  F-6
  ADVANCED
        PLANT PHARMACEUTICALS, INC. AND SUBSIDIARIES
 
 NOTES
        TO
        FINANCIAL STATEMENTS
 March
        31,
        2007
  8.
        GOING
        CONCERN UNCERTAINTY AND MANAGEMENT’S PLANS
  As
        reflected in the accompanying financial statements, the Company has current
        liabilities in excess of current assets of $2,436,537, resulting in negative
        working capital and an accumulated deficit of $24,852,944. Management is
        presently seeking to raise permanent equity capital in the capital markets
        to
        eliminate negative working capital and provide working capital. Failure to
        raise
        equity capital or secure some other form of long-term debt arrangement will
        cause the Company to further increase its negative working capital deficit
        and
        could result in the Company having to curtail or cease operations. Additionally,
        even if the Company does raise sufficient capital to support its operating
        expenses and generate revenues, there can be no assurances that the revenue
        will
        be sufficient to enable it to
        develop business to a level where it will generate profits and cash flows
        from
        operations. These matters raise substantial doubt about the Company’s ability to
        continue as a going concern. However, the accompanying financial statements
        have
        been prepared on a going concern basis, which contemplates the realization
        of
        assets and satisfaction of liabilities in the normal course of business.
        These
        financial statements do not include any adjustments relating to the recovery
        of
        the recorded assets or the classification of the liabilities that might be
        necessary should the Company be unable to continue as a going
        concern.
  9.
        RECLASSIFICATIONS
 
 Certain
        reclassifications have been made to the financial statements for the three
        months ended March 31, 2006 to conform to the presentation used in the financial
        statements as of March 31, 2007 and for the three month period then
        ended.
 
 10.
        SUBSEQUENT EVENT
 
 Agreement
        of Settlement and Release
 
 On
        April
        20, 2007, the Company approved an agreement of settlement and release with
        the
        President and sole Director of the Company. Pursuant to the terms of the
        agreement, the Company will transfer 200,000 shares of common stock in Amazon
        Biotech, Inc. (“Amazon”) it holds to the President in payment of accrued
        salaries in the amount of $12,000. The common stock of Amazon closed at $0.08
        per share on April 20, 2007, which will result in stock based compensation
        being
        recorded in the amount of $4,000.
 
 F-7


RISK
      FACTORS




Item
        1A.




Except
      as
      stated herein, t here
      have
      been no material changes in our risk factors from those disclosed in our 2006
      Annual Report on Form 10-KSB.




Item 2.
      Management’s Discussion and Analysis of Financial Condition and Results of
      Operation




THE
      FOLLOWING DISCUSSION OF THE RESULTS OF OUR OPERATIONS AND FINANCIAL CONDITION
      SHOULD BE READ IN CONJUNCTION WITH OUR FINANCIAL STATEMENTS AND THE NOTES
      THERETO INCLUDED ELSEWHERE IN THIS REPORT.





CAUTIONARY
      NOTE REGARDING FORWARD-LOOKING STATEMENTS





Certain
      statements in this quarterly report on Form 10-QSB contain or may contain
      forward-looking statements that are subject to known and unknown risks,
      uncertainties and other factors which may cause actual results, performance
      or
      achievements to be materially different from any future results, performance
      or
      achievements expressed or implied by such forward-looking statements. These
      forward-looking statements were based on various factors and were derived
      utilizing numerous assumptions and other factors that could cause our actual
      results to differ materially from those in the forward-looking statements.
      These
      factors include, but are not limited to, economic, political and market
      conditions and fluctuations, government and industry regulation, interest rate
      risk, U.S. and global competition, and other factors. Most of these factors
      are
      difficult to predict accurately and are generally beyond our control. You should
      consider the areas of risk described in connection with any forward-looking
      statements that may be made herein. Readers are cautioned not to place undue
      reliance on these forward-looking statements, which speak only as of the date
      of
      this report. Readers should carefully review this quarterly report in its
      entirety, including but not limited to our financial statements and the notes
      thereto. Except for our ongoing obligations to disclose material information
      under the Federal securities laws, we undertake no obligation to release
      publicly any revisions to any forward-looking statements, to report events
      or to
      report the occurrence of unanticipated events. For any forward-looking
      statements contained in any document, we claim the protection of the safe harbor
      for forward-looking statements contained in the Private Securities Litigation
      Reform Act of 1995.




GENERAL





APPI
      focuses on the research and development of plant based dietary supplements.
      During July 1999, the Company acquired exclusive rights and interests to a
      thirteen-step process, which utilizes virtually the whole of the nutrients
      found
      in plants to manufacture all natural herbal dietary supplements. The Company
      intends to use this process to manufacture products that it hopes to distribute
      worldwide through various sales distribution contracts.





Our
      products we are currently marketing are:




· Lo-Chol
        - Lo-Chol's patent pending formula is derived from the "whole plant" parts
        of
        six selected plants that work in concert to help tip your lipid balance (good
        and bad cholesterol) towards a more normal level. These six plants are
        synergistically combined using a proprietary "whole plant technology" (a
        special
        pharmaceutical-grade process) that delivers virtually all the natural
        phyto-chemicals and active ingredients in the plants. Unlike almost all other
        herbal supplements on the market, Lo-Chol does not contain any extracts.
        Instead, it utilizes the entire part of a specific plant that is processed
        and
        standardized to deliver optimum potency and nutritional benefits.
  · ACA -
          ACACaplets contain a carefully selected group of 11 natural plant substances,
          which work in harmony to help chronic fatigue and boost normal metabolic
          processes that support immune system function. These 11 plants (including
          Boswelliacaterii, Impatiens balaminia and Curcuma zedoria) have long and
          storied
          histories in ancient herbal medicine and folklore. Many are referred to
          in the
          Bible as well as Ayurveda, "India's natural science of life and well-being".
          Now, incorporated together in ACA, they offer the best of traditional herbal
          wisdom and modern science.


2


· Sinusol
        - Developed in concert with a leading board certified Allergy and Sinus
        specialist, SINUSOL(TM) is a unique nasal and sinus solution that pleasantly
        cleanses and moisturizes the nasal and sinusmucosa. Sinusol(TM) thins nasal
        solutions to clear stuffy and blocked allergic nasal passages as well as
        relieves sneezing and sinus pressure. Sinusol(TM), is the safe and natural
        alternative to over the counter nasal sprays and saline products that contain
        irritating preservatives and additives.




Management
      has not been satisfied with the results of its operations in this field. Due
      to
      limited capital resources, it has not been able to properly promote or advertise
      its products. Moreover, even with increased brand awareness, competition in
      the
      field remains intense. As a result the Company is pursuing other business
      opportunities and has acquired all of the issued and outstanding shares of
      common stock of World Health Energy, Inc. (“WHE”).





World
      Health Energy Inc. is a developmental stage company with no operations to date.
      Subject to receipt of financing, of which there can be no assurance, its primary
      business objective is to produce and market high-quality, low-cost B100
      biodiesel. In addition to the production of biodiesel, WHE intends to design
      and
      manufacture biodiesel production plants in varying capacities to meet the demand
      of the market, thereby, providing much needed complementary renewable energy
      solutions to the international biodiesel communities. WHE hopes to establish
      strategic alliances and partnerships with proposed leased and owned facilities
      and make resale arrangements with energy suppliers.





Assuming
      the Company can raise sufficient finances, they intend to focus their operations
      on World Health.





**Comparison
      of Operating Results for the Quarter Ended March 31, 2007 to the Quarter Ended
      March 31, 2006**




Revenues





For
      the
      three months ended March 31, 2007 as compared to the three months ended March
      31, 2006, we generated revenue of $ **4,037** as
      compared to $ **1,976** .





Net
      Loss





Net
      loss
      for the three months ended March 31, 2007 was $484,940 as compared to a loss
      of
      $638,774 in the comparable period in 2006.





Operating
      Expenses





Salaries
      and consulting fees - stockholders' for both quarters were $79,500. Selling,
      general and administrative costs were $408,671 as compared to $24,024. Most
      of
      the operating expenses we incurred for the quarter represented stock issued
      for
      services rendered.





Liquidity
      and Capital Resources





We
      have
      total assets of $350,561 as compared to $29,694 as of December 31, 2006. We
      have
      recorded $328,648 as goodwill from the acquisition of World Health Energy,
      Inc.
 At the time of the acquisition of WHE, WHE had assets of $1,352. We are
      obligated to issue to the shareholders of WHE a total of 55 million shares
      of
      our common stock which we have valued at $330,000. The difference between WHE’s
      book value and the value of our common stock has been recorded as
      goodwill.


3


We
      use
      available finances to fund ongoing operations. Funds will be used for general
      and administrative expenses, We do not have sufficient funds available to meet
      our current liabilities. Unless we secure additional financing, it is unlikely
      that we will be able to continue our current operations.




We
      have
      current liabilities totaling $2,436,537 as compared to $1,799,134 as of December
      31, 2006. Our accounts payable and accrued expenses total $184,447 and $443,931
      respectively as compared to $181,946 and $425,694 at December 31, 2006.
      Amounts **** due
      to
      stockholders total $1,278,331 as compared to $1,177,542. This amount includes
      loans of $332,470 in 2007 and $305,993 in 2006. We are also obligated to issue
      $350,000 of our common stock, $50,000 pursuant to a stock purchase agreement
      and
      $300,000 per the WHE acquisition agreement and have recorded $119,096 in
      accrued expenses payable in common stock. We have also received $50,000 pursuant
      to a $1,200,000 financing for a 33% interest in the company in the form of
      convertible preferred stock, which to date has not been issued. Since we do not
      have a sufficient number of shares available to issue under our articles of
      incorporation, we will be required to increase the number of authorized shares
      and/or implement a reverse split of our common stock.





Going
      concern





As
      reflected in the accompanying financial statements, the Company has current
      liabilities in excess of current assets of $2,436,537, resulting in negative
      working capital and an accumulated deficit of $24,852,944 .
      Management is presently seeking to raise permanent equity capital in the capital
      markets to eliminate negative working capital and provide working capital.
      Failure to raise equity capital or secure some other form of long-term debt
      arrangement will cause the Company to further increase its negative working
      capital deficit and could result in the Company having to curtail or cease
      operations. Additionally, even if the Company does raise sufficient capital
      to
      support its operating expenses and generate revenues, there can be no assurances
      that the revenue will be sufficient to enable it to develop business to a level
      where it will generate profits and cash flows from operations. These matters
      raise substantial doubt about the Company’s ability to continue as a going
      concern. However, the accompanying financial statements have been prepared
      on a
      going concern basis, which contemplates the realization of assets and
      satisfaction of liabilities in the normal course of business. These financial
      statements do not include any adjustments relating to the recovery of the
      recorded assets or the classification of the liabilities that might be necessary
      should the Company be unable to continue as a going concern.




ITEM
      3.
      CONTROLS AND PROCEDURES





As
      of the
      end of the period covered by this Report, the Company's chief executive officer
      and its principal financial officer, (the “Certifying Officers”) evaluated the
      effectiveness of the Company's "disclosure controls and procedures," as defined
      in Rule 13a-15(e) under the Securities Exchange Act of 1934. David Lieberman,
      is
      our chief executive officer and chief financial officer. Based on that
      evaluation, the Certifying Officers concluded that, as of the date of their
      evaluation, the Company's disclosure controls and procedures were effective
      to
      provide reasonable assurance that information required to be disclosed in the
      Company's periodic filings under the Securities Exchange Act of 1934 is
      accumulated and communicated to management, including these officers, to allow
      timely decisions regarding required disclosure.





The
      Certifying Officers have also indicated that there were no significant changes
      in our internal controls or other factors that could significantly affect such
      controls subsequent to the date of their evaluation and there were no corrective
      actions with regard to significant deficiencies and material
      weaknesses.





Notwithstanding
      the foregoing, management has determined that stricter controls regarding the
      issuance of its common stock are in order. Specifically, since David Lieberman
      is currently the sole officer and director of the Company, all common stock
      issuance have been pursuant to written consent of the sole directors. All of
      these actions have not been communicated to the Company’s transfer agent which,
      had these measures been properly taken, resulted in the issuance of common
      stock
      beyond the authorized capitalization of the Company. Management has for the
      future undertaken to confirm with third parties regarding the validity of any
      stock issuance and to immediately forward all board resolutions to the Company’s
      transfer agent.




4




Our
      management, including the Certifying Officers, do not expect that our disclosure
      controls or our internal controls will prevent all errors and fraud. A control
      system, no matter how well conceived and operated, can provide only reasonable,
      not absolute, assurance that the objectives of the control system are met.
      In
      addition, the design of a control system must reflect the fact that there are
      resource constraints, and the benefits of controls must be considered relative
      to their costs. Because of the inherent limitations in all control systems,
      no
      evaluation of controls can provide absolute assurance that all control issues
      and instances of fraud, if any, within a company have been detected. These
      inherent limitations include the realities that judgments in decision-making
      can
      be faulty, and that breakdowns can occur because of simple error or mistake.
      Additionally, controls can be circumvented by the individual acts of some
      persons, by collusion of two or more people or by management override of the
      control. The design of any systems of controls also is based in part upon
      certain assumptions about the likelihood of future events, and there can be
      no
      assurance that any design will succeed in achieving its stated goals under
      all
      potential future conditions. Because of these inherent limitations in a
      cost-effective control system, misstatements due to error or fraud may occur
      and
      not be detected.




PART
      II.
      OTHER INFORMATION




Item
      1.  Legal
      Proceedings.




None




Item
      2.
      Unregistered Sales of Equity Securities,




During
      the quarter ended March 31, 2007 we issued the following unregistered
      securities:




On
      February 8, 2007 we issued a total of 5,000,000 shares of our common stock
      to
      the two shareholders of World Health Energy, Inc. in exchange for all of the
      issued and outstanding shares of common stock of World Health Energy, Inc.




The
      securities issued in the foregoing transactions were made in reliance upon
      an
      exemption from registration under Section 4(2) of the Securities Act.
      Alternatively, these issuances of securities were undertaken under Rule 506
      of
      Regulation D under the Securities Act of 1933, as amended, by the fact
      that:




Also
      during the quarter ended March 31, 2007 we issued a total of 77 million shares
      of our registered Common Stock to various consultants for services rendered.
      The
      Shares were issued from our various Stock Incentive Plans which were filed
      on
      Form S-8 with the Securities and Exchange.




We
      have
      also authorized the issuance of an additional 107,157,996 shares of our common
      stock in excess of the authorized number of shares. None of these shares will
      be
      issued until the Company’s amends its articles of incorporation to increase the
      number of authorized shares.




Item
      3.  Defaults
      upon senior securities.




None.




Item
      4.
      Submission of matters to a vote of security holders.


5


There
      were no matters submitted during the quarter ended March 31, 2007 to a vote
      of
      the Company’s securities holders.




Item 5.
      Exhibits and Report on Form 8-K




During
      the quarter ended March 31, 2007 we filed a report on February 9, 2007 on
      Form 8-k in connection with our acquisition of World Health Energy, Inc.




Exhibit
                  No.
              
              Description31.1
              
              Section
                  302 Certification of the Principal Executive Officer *31.2
              
              Section
                  302 Certification of the Principal Financial Officer *32.1
              
              Section
                  906 Certification of Principal Executive Officer *32.2
              
              Section
                  906 Certification of Principal Financial and Accounting Officer
                  *




*
      Filed
      herewith






SIGNATURES





In
      accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused
      this report to be signed on its behalf by the undersigned, thereunto duly
      authorized.





ADVANCED
      PLANT PHARMACEUTICALS, INC.


Date:
        May
        18 , 2007


By:
            /s/
              David LiebermanDavid
                LiebermanCEO
                and Director




In
      accordance with the Exchange Act, this report has been signed below by the
      following persons on behalf of the registrant and in the capacities and on
      the
      dates indicated.




By:
            /s/
              David
              Lieberman
            
            
            Date:
                May 18 , 2007David
                LiebermanCEO/
                Director




6